Case Study: US FDA approves erythroid maturation agent, Reblozyl
Bristol Myers Squibb and Acceleron Pharma Inc, a biopharmaceutical company, announced the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt),... Read More
Bristol-Myers Squibb to acquire Celgene in deal worth $74 billion
Posted on07 Jan 2019
Comments0
BMS - Celgene acquisition deal
Bristol-Myers Squibb, Infinity Pharma ink clinical collaboration deal
Posted on06 Nov 2018
Comments0
Bristol-Myers Squibb Company and Infinity Pharmaceuticals, Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549... Read More
Transgene, BMS’s clinical research deal
Posted on28 Apr 2017
Comments0
Bristol-Myers Squibb Company and Transgene announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic... Read More
BMS exclusive worldwide license agreement with PsiOxus Therapeutics for NG-348
BMS and PsiOxus Therapeutics, Ltd. announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus... Read More
CHAI announces partnership with governments in six low- and middle-income countries to initiate and expand hepatitis C treatment programs
Ministries of Health in Ethiopia, Indonesia, Myanmar, Nigeria, Rwanda, and Vietnam are accelerating access to hepatitis C (HCV) testing and treatment with... Read More
ViiV Healthcare acquires late-stage HIV R&D assets from BMS
GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, announced that ViiV Healthcare, the global specialist HIV company majority... Read More
BMS and Pfizer sign collaboration with Portola Pharmaceuticals
Posted on08 Feb 2016
TagsBMS, BMS and Pfizer sign collaboration with Portola Pharmaceuticals, pfizer, Portola Pharmaceuticals
Comments0
Bristol-Myers Squibb Company and Pfizer Inc. have entered into a collaboration agreement with Portola Pharmaceuticals Inc. to develop and commercialize the investigational... Read More
BMS gets rights to acquire Promedior & its anti-fibrosis drug, PRM-151
Bristol-Myers Squibb Company and Promedior, Inc., have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and... Read More
R-PHARM US Acquires IXEMPRA(R) (ixabepilone) From Bristol-Myers Squibb and Launches U.S. Commercial Operations
R-PHARM US announces the acquisition of IXEMPRA (ixabepilone) from Bristol-Myers Squibb (BMY). IXEMPRA received marketing approval from the U.S. Food and Drug... Read More